Cleo Diagnostics shares its updated June 2025 corporate presentation outlining the Company's strategy and progress on "Pioneering the Transformation of Ovarian Cancer Detection."
The clinical unmet need for a screening solution for Ovarian Cancer is urgent.
Critically, no effective screening test currently exists, with the only way to definitively diagnose Ovarian Cancer being after surgery.
51% of women continue to die within 5 years of an Ovarian Cancer diagnosis. That’s 6 times higher than for Breast Cancer which has a mortality rate of only 8%.
CLEO’s disruptive patented technology offers superior performance to current clinical tests with the Company advancing its plans to address a critical unmet need on a global scale.
Link to presentation: bit.ly/43Gikp9
Dayna Louca
Head of Corporate Development
Cleo Diagnostics Limited
[email protected]
